Market & RegulationInvestment · $2.1B
Biotech Investment Steady Amid AI Funding Surge
Crunchbase Newshigh confidence
Why it matters
- →Biotech investment remains stable despite the AI funding surge.
- →AI-focused biotech companies are attracting significant investments.
- →Early-stage investments and IPOs indicate a healthy biotech pipeline.
Biotech startups have maintained steady investment levels, with global funding ranging from $36 billion to $40 billion, even as AI funding surges. AI-focused biotech companies, like Isomorphic Labs, have secured significant investments, with a $2.1 billion Series B round marking the largest for any biotech this year. The sector continues to see early-stage investments and IPOs, suggesting a robust pipeline. Despite the AI investment boom, biotech remains a stable and promising field for investors.
Read originalThe story around this
Earlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
More from Crunchbase News
More in Market & Regulation
© TechCrunch AIMarket & Regulationother
Judge allows NAACP lawsuit over xAI pollution to proceed
xAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
TechCrunch AI
© TechCrunch AI
